Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 10/20 | 0.59 |
| ▸ | BACE2 | Q9Y5Z0 | 4/20 | 0.59 |
| ▸ | NPY4R | P50391 | 6/20 | 0.58 |
| ▸ | NPY1R | P25929 | 5/20 | 0.58 |
| ▸ | NPY2R | P49146 | 3/20 | 0.58 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.55 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.52 |
| ▸ | CTSD | P07339 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30512662 | 0.93 | NPY4R (0.62) | BACE1BACE2NPY4RNPY1RNPY2R | |
| SCHEMBL32677746 | 0.93 | BACE1 (0.59) | BACE1BACE2NPY4RNPY1RNPY2R | |
| SCHEMBL30647291 | 0.93 | BACE1 (0.59) | BACE1BACE2NPY4RNPY1RNPY2R | |
| SCHEMBL31353030 | 0.91 | NPY4R (0.57) | BACE1BACE2NPY4RNPY1RNPY2R | |
| SCHEMBL30607418 | 0.91 | BACE1 (0.60) | BACE1BACE2NPY4RNPY1RNPY2R | |
| SCHEMBL30320569 | 0.91 | BACE1 (0.58) | BACE1BACE2CTSD | |
| SCHEMBL30799753 | 0.90 | NPY4R (0.66) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL31433352 | 0.90 | NPY4R (0.59) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL30880877 | 0.90 | BACE1 (0.59) | BACE1BACE2NPY4RNPY1RNPY2R | |
| SCHEMBL30130346 | 0.90 | BACE1 (0.57) | BACE1BACE2PTPN1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | CALICO LIFE SCIENCES LLC (US) | 2025-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | MICA, CD74, HLA-DRB1 | BACE1 2095/4885BACE2 3003/4885NPY4R 1616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.